These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31525626)

  • 21. Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice.
    Kravvariti E; Kasdagli MI; Diomatari KM; Mouratidou P; Daskalakis K; Mitsikostas DD; Sfikakis PP; Yavropoulou MP
    Osteoporos Int; 2023 Mar; 34(3):585-598. PubMed ID: 36596944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials.
    Varma A; Zis P
    Acta Neurol Belg; 2019 Jun; 119(2):257-264. PubMed ID: 31004288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
    Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
    Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
    Kokoti L; Drellia K; Papadopoulos D; Mitsikostas DD
    J Neurol; 2020 Apr; 267(4):1158-1170. PubMed ID: 31919565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
    Papadopoulos D; Mitsikostas DD
    CNS Drugs; 2018 Nov; 32(11):1069-1078. PubMed ID: 30069684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nocebo Responses in Brain Diseases: A Systematic Review of the Current Literature.
    Zis P; Mitsikostas DD
    Int Rev Neurobiol; 2018; 139():443-462. PubMed ID: 30146057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy.
    Marangi A; Farina G; Vicenzi V; Forlivesi S; Calabria F; Marchioretto F; Forgione A; Rossi F; Stenta G; Vianello M; Gajofatto A; Benedetti MD
    Mult Scler Relat Disord; 2020 Jun; 41():102004. PubMed ID: 32078935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice.
    Mitsikostas DD; Chalarakis NG; Mantonakis LI; Delicha EM; Sfikakis PP
    Eur J Neurol; 2012 May; 19(5):672-80. PubMed ID: 21973313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nocebo in clinical trials for depression: a meta-analysis.
    Mitsikostas DD; Mantonakis L; Chalarakis N
    Psychiatry Res; 2014 Jan; 215(1):82-6. PubMed ID: 24210741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials.
    Zis P; Mitsikostas DD
    J Neurol Sci; 2015 Aug; 355(1-2):94-100. PubMed ID: 26073486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nocebo responses in randomized controlled trials of COVID-19 vaccines.
    Lee YH; Song GG
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):5-12. PubMed ID: 34622766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Baroncini D; Zaffaroni M; Moiola L; Lorefice L; Fenu G; Iaffaldano P; Simone M; Fanelli F; Patti F; D'Amico E; Capobianco M; Bertolotto A; Gallo P; Margoni M; Miante S; Milani N; Amato MP; Righini I; Bellantonio P; Scandellari C; Costantino G; Scarpini E; Bergamaschi R; Mallucci G; Comi G; Ghezzi A
    Mult Scler; 2019 Mar; 25(3):399-407. PubMed ID: 29363396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.